期刊文献+

吉非替尼合成方法改进 被引量:3

Improved Synthesis of Gefitinib
下载PDF
导出
摘要 本文报道一条简单有效的合成吉非替尼的工艺路线。以3-羟基-4-甲氧基苯甲醛为起始原料,将其醛基转化为氰基后再与N-(3-氯丙基)吗啉缩合,然后依次经硝化、水解、还原、环合等操作得到重要的中间体7,最后经氯化后与3-氯-4-氟苯胺缩合以总收率48%得到吉非替尼。其中对如下过程进行优化:硝化反应后处理改用NaOH中和酸,然后过滤纯化;硝基还原反应改用甲酸铵、Pd/C的催化的条件;环合反应后处理采用蒸馏的方法除去甲酸,这些改进显著提高了反应总收率。 A convenient procedure for the synthesis of gefitinib is described.Important intermediate 7 was obtained from 3-hydroxy-4-methoxybenzaldehyde via conversion of aldehyde to nitrile,followed by alkylation with N-(3-chloropropy1)morpholine,nitration,hydrolization,reduction,cyclization and finally subjected to chlorination and condensation with 3-chloro-4-fluoroaniline.The procedure was improved and the overall yield was raised to 48% by optimizing the following procedures: NaOH was employed for neutralization in the post-processing of nitration reaction and then purified by filtration;ammonium formate was used as the hydrogen donor in the Pd/C catalyzed reduction and finally in the post-processing of cyclyzation,formic acid was removed by distillation.
出处 《中国海洋大学学报(自然科学版)》 CAS CSCD 北大核心 2010年第8期103-106,共4页 Periodical of Ocean University of China
关键词 吉非替尼 EGFR酪氨酸激酶抑制剂 合成 gefitinib EGFR tyrosine kinase inhibitors synthesis
  • 相关文献

参考文献14

  • 1Schlesinger J.Cell signaling by receptor tyrosine kinases[J].Cell,2000,103,211-225.
  • 2Hubbard R D,Bamaung N Y,Fidanze S D,et al.Development of multitargeted inhibitors of both the insulin-like growth factor receptor (IGF-IR) and members of the epidermal growth factor family of receptor tyrosine kinases[J].Bioorg.Med.Chem.Lett.2009,19,1718-1721.
  • 3Rheault T R,Caferro T R,Dickerson S H,et al.Thienopyrimidine-based dual EGFR/ErbB-2 inhibitors[J].Bioorg.Med.Chem.Lett.,2009,19,817-820.
  • 4Frampton J E,Easthope S E.Gefitinib[J].Drugs,2004,64(21):2475-2492.
  • 5黄世杰.AstraZeneca公司的gefitinib有希望复合治疗非小细胞肺癌[J].国外医学(药学分册),2003,30(2):118-118. 被引量:4
  • 6张艳华,宁华,姜洋.表皮生长因子受体酪氨酸激酶抑制剂吉非替尼[J].中国新药杂志,2004,13(10):947-950. 被引量:13
  • 7Gibson K H.Preparation of haloanilinoquinazolines as Class I receptor tyrosine kinase inhibitors:WO,9633980[P].1996-10-31.
  • 8金波,陈国华,邹爱峰,石涛,任金山.吉非替尼的合成[J].中国药科大学学报,2005,36(1):92-94. 被引量:11
  • 9Li M D,Zheng Y G,Ji M.Synthesis of Gefitinib from Methyl 3-Hydroxy-4-methoxy-benzoate[J].Molecules,2007,12,673-678.
  • 10江苏吴中苏药医药开发责任有限公司.4-(3-氯-4-氟苯基氨基)-7-甲氧基-6-(3-吗啉丙氧基)-4-喹唑啉.CN 1733738.2006-02-15.

二级参考文献27

  • 1张艳华,宁华,姜洋.表皮生长因子受体酪氨酸激酶抑制剂吉非替尼[J].中国新药杂志,2004,13(10):947-950. 被引量:13
  • 2[1]Natale R,Zaretsky SL.ZD1839 (IressaTM):what's in it for the patient[J].The Oncologist,2002,7(Suppl 4):S25-S30.
  • 3[2]Herbst RS,Kies MS.ZD1839 (IressaTM) in non-small-cell lung cancer[J].The Oncologist,2002,7(Suppl 4):S9-S15.
  • 4[3]Barker AJ,Gibson KH,Grundy W,et al.Studies leading to the identification of ZD1839(IRESSA):an orally active,selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer[J].Bioorg Med Chem,2001,11(14):1911-1914.
  • 5[4]Iwasawa A,Kumamoto Y,Fujinaga K.Detection of human papillomavirus deoxyribonucleic acid in penile carcinoma by polymerase chain reaction and in situ hybridization[J].J Urol,1993,149(1):59-63.
  • 6[5]Varma VA,Sancher LMM,Unger ER,et al.Association of human papillomavirus with penile carcinoma:a study using polymerase chain reaction and in situ hybridization[J].Hum Pathol,1991,22(9):908-913.
  • 7[6]Gorgoulis V,Aninos D,Mikou P,et al.Quantitative assay of epidermal growth rceptor in squamous cell lung carcinomas[J].Anti Cancer Res,1992,12(4):1183.
  • 8[7]Swaisland H,Laight A,Stafford L,et al.Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers[J].Clin Pharmacokinet,2001,40(4):297-306.
  • 9[8]Alderley P.ZD1839 ('Iressa'),an oral EGFR-TKI:pharmacokinetic results of a phase Ⅰstudy in patients with advanced cancer[A].AACR[C].San Francisco,CA,April 1-5,2000.
  • 10[9]Fukuoka M,Yano S,Giaccone G,et al.Final results from a Phase Ⅱ trial of ZD1839 ('Iressa') for patients with advanced non-small-cell lung cancer (IDEAL 1)[J].Proc Am Soc Clin Oncol,2002,21:298a(A1188).

共引文献26

同被引文献26

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部